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ABSTRACT 
Background Atypical hemolytic uremic syndrome (aHUS) is a form of TMA caused by 
dysregulation of the complement system. The outcome of kidney transplantation is poor 
due to aHUS recurrence and loss of the graft. Patients carrying CFH mutations or 
CFH/CFHR1 hybrid genes present very high risk of recurrence despite preventive 
plasmapheresis. Evaluation of recent data suggests that prophylactic Eculizumab 
pretransplant is the prefered therapy if drug is available. 
Case-diagnosis/treatment We report three year follow-up data in a 9-year-old boy with 
aHUS and successful renal transplant treated with prophylactic eculizumab without 
recurrence. He presented with aHUS at age 3, irreversible renal failure and uncontrolled 
severe hypertension with concentric left ventricular hypertrophy, recurrent acute 
pulmonary edema and congestive heart failure despite 5 hypotensive agents and bilaeral 
nephrectomy. Complement analysis demonstrated the presence in the patient of a 
CFH/CFHR1 hybrid gene inherited from his mother and a SNP risk CFH haplotype 
inherited from his father. Kidney transplant was performed with prophylactic 
eculizumab and subsequent fortnightly administration. Three years post-transplant, graft 
function remains stable (serum creatinine 0.9 mg/dl), hypertension is controlled, no left 
ventricular hypertrophy, no opportunistic infections and negative clinical chemistry 
parameters for hemolysis. 
 Conclusion Eculizumab is a safe and effective therapy to prevent TMA recurrence and 
provides long-term graft function in aHUS with CFH/CFHR1 hybrid gene. 
 
Key words: Atypical hemolytic uremic syndrome, eculizumab, renal transplant 
recipient, CFH/CFHR1 hybrid gene 
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INTRODUCTION 
Atypical hemolytic uremic syndrome (aHUS) is a form of TMA caused by 
dysregulation of the complement system. Prognosis is poor and over half of patients 
progress to end-stage renal failure or die. Conventional renal transplant is not a safe 
treatment option due to the high risk of recurrence and loss of the graft (1). Patients on 
dialysis have poorer chances of survival and present cardiovascular risk secondary to 
hypertension. The efficacy of plasmapheresis is transient and the morbidity/mortality 
rates for combined liver-kidney transplant are high. 
 
Eculizumab is a humanized anti-C5 monoclonal antibody that blocks activation of the 
terminal complement cascade. It has recently been approved for the treatment of aHUS 
and  shown to be effective both in native and non-native kidney. 9 patients had received 
prophylactic eculizumab to prevent  posttransplant aHUS recurrence (2).  
 
We report three year follow-up data in a boy with aHUS and renal transplant treated 
with prophylactic eculizumab without recurrence. 
 
CASE REPORT 
Our 9-year-old patient presented at age  3 with oliguric renal failure, microangiopathic 
hemolytic anemia with schistocytes and thrombocytopenia. He had no diarrhea or 
neurological symptoms, stool cultures were negative. Hypertension, hematuria and 
nephrotic syndrome were present from onset (serum creatinine 2.57 mg/dl, creatinine 
clearance 20 ml/min/1.73 m2, hemoglobin 8.8 g/dl, platelets 55,000/mm3, LDH 2445 
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UI, undetectable haptoglobin, nephrotic proteinuria, albumin 2,7 g/dl). Hemodialysis 
was started on day 9 with serum creatinine of 5.8 mg/dl, thrombocytopenia 
(31,000/mm3). Anemia (Hb 5.8 g/dl) persisted despite 5 transfusions of cell concentrate 
in the first month.  
 
Continuing on dialysis for 4 years the patient had two further hemolytic crises requiring 
transfusion and also experienced persistent headaches, abdominal pain, paresthesia and 
general malaise. The clinical course was dominated by uncontrolled hypertension with 
concentric left ventricular hypertrophy despite daily hemodialysis and 5 hypotensive 
agents. He suffered three hypertensive crises with acute pulmonary edema and 
congestive heart failure. In view of life-threatening hypertension, bilateral nephrectomy 
was decided three months after initial onset. Renal pathology showed cortical 
glomerular cystic transformation and severe arteriosclerosis. However, severe 
hypertension continued to be poorly-controlled. He had two further hypertensive crises, 
the second being 2.5 years after onset and involving hypertonic seizure and 
cardiorespiratory arrest.  
 
COMPLEMENT ASSESSMENT 
Complement analysis in the patient and their relatives illustrated normal levels of C3, 
C4, FI, FB and FH. Assays to identify C3Nef or anti-FH autoantibodies were negative. 
Levels of MCP on the surface of peripheral blood lymphocytes were also normal. 
Functional analysis of FH, using a sheep red cell hemolytic assay (3), demonstrated  an 
abnormal FH activity in the patient and in three of his relatives (Table 1), which 
suggested that the patient and his relatives carry a functional alteration in the C-terminal 
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region of FH. Importantly, this type of functional alteration in FH is prototypical of 
aHUS (4).    
Sequencing analyses identified that the patient and the relatives with functional 
alteration in FH carry two genetic variations in the CFH gene (c.2669G>T, p.Ser890Ile 
and c.3019G>T, p.Val1007Leu) in heterozygozygosis (Suppl. Figure 1). In addition, 
multiplex ligation-dependent probe amplification (MLPA) identified in these 
individuals a genetic rearrangement in the CFH-CFHR region resulting in a 
CFH/CFHR1 hybrid gene similar to that previously found in other aHUS patients 
(Table 1; Supp. Figure 1) (5). The product of this hybrid gene is a mutant FH protein in 
which the C-terminal region is substituted for the C-terminal region of FHR1, 
introducing two amino acid changes, Ser1191Leu and Val1197Ala. Interestingly, the 
Ser890Ile and Val1007Leu genetic variations and the hybrid gene segregate together in 
the same CFH allele. In summary, the FH protein encoded by this CFH/CFHR1 gene 
presents four amino acid differences compared to the FH reference protein (Supp. 
Figure 1). No mutations were found in CFI, MCP, C3, CFB and THBD.  
 
KIDNEY  TRANSPLANTATION UNDER ECULIZUMAB 
The patient’s condition on hemodialysis continued to be life-threatening. Published 
results showing effective inhibition of complement mediated TMA by eculizumab in 
aHUS (6,7). In 2010, four years after onset, deceased donor kidney transplant was 
proposed with pre-emptive eculizumab treatment. Informed consent was obtained from 
the family for treatment under terms of compassionate use.  
 
Prior to transplant he was appropriately immunized against haemophilus influenzae, 
pneumococcus, viral hepatitis B, varicella and tetravalent meningococcal vaccine. Anti-
HLA antibodies were negative. Kidney transplant was scheduled with induction with 
basiliximab, prednisone, mycophenolate mofetil and tacrolimus, plus prophylactic 
eculizumab. The regimen consisted of administration of the first dose of eculizumab 
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600 mg 6 hours pre-transplant, then within 24 hours, then 4 weekly doses and 
subsequently, doses of 600 mg in fortnightly cycles.  
 
Kidney transplant was performed from deceased donor with 3 compatibilities. There 
was immediate diuresis on unclamping. Serum creatinine decreased from 9 to 0.7 mg/dl 
over the initial few weeks post-transplant. There were no side effects after 
administration of eculizumab. He was started on tacrolimus on day +2 , the steady 
decrease in creatinine continued. He received prophylaxis with valganciclovir, co-
trimoxazole and phenoxybenzylpenicillin (ongoing).  
 
In the first week post-transplant, the patient developed a surgical complication 
consisting of punctiform intestinal perforation without TMA signs resolved by simple 
suturing. One month after surgery, a bladder fistula was resolved with a double J stent. 
He developed Klebsiella pyelonephritis related to the catheter which was resolved 
without complications. There were no clinical or laboratory signs showing complement 
activity during the episodes of infection, thus requiring no modification of the 
eculizumab treatment regimen.  
 
Three years post-transplant, graft function continues stable, serum creatinine 0.9 mg/dl, 
no proteinuria, Hb 11.9 g/dl, normal platelets, hypertension controlled with calcium 
channel blocker and beta blocker without ventricular hypertrophy, no cytotoxic 
antibodies, negative BK viruria, no CMV infection and negative clinical chemistry 
parameters for hemolysis. He has remained free of any further evidence of TMA with 
fortnightly administration as an outpatient of eculizumab, the current dose of 900 mg 
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adjusted to body weight. His growth is normal, as with his activities and performance at 
school, with full social and familial integration. 
 
DISCUSSION 
Our experience supports the utility and safety of eculizumab for the prevention of aHUS 
recurrence post-transplant in patients carrying a CFH/CFHR1 hybrid gene. There are 
reports of 9 patients with aHUS who have been treated with eculizumab prior to renal 
transplant in the literature, four cases with prophylactic plasma therapy preceded 
eculizumab and five with eculizumab alone (2). Two patients  had a CFH/CFHR1 
hybrid gene (8,9). Our patient´s outcome is favorable and renal function normal 36  
months after kidney transplantation without recurrence. He remains free of any further 
clinical TMA manifestations taking eculizumab alone. 
 
The genetic analysis allow us to conclude that the CFH/CFHR1 hybrid gene is the 
underlying genetic defect responsible of aHUS in our patient. The FH/FHR1 hybrid 
protein encoded by this gene is unable to provide appropriate regulation of the C3 
convertase, exposing platelets and endothelium to the uncontrolled activation of the 
complement pathway that characterises aHUS. The CFH/CFHR1hybrid gene in our 
patient carry two additional nucleotide changes that are irrelevant. In fact, in a separate 
study, we have recently shown that Ser890Ile and Val1007Leu genetic variations are 
polymorphisms with no functional consequences (10). The CFH/CFHR1 hybrid gene 
was inherited from the mother and likely originated earlier in that lineage, since is it 
also found in one of the patient’s aunts. The CFH/CFHR1 hybrid gene is necessary but 
not sufficient to develop aHUS, as is clearly illustrated by the fact that three other 
relatives carrying it have not developed aHUS. Previously, it has been shown that the 
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incomplete penetrance of the disease in carriers of mutations associated with aHUS can 
be explained by the concurrence of additional genetic or environmental factors (11, 12). 
Analysis of the levels of expression of the normal and mutant CFH alleles in the carriers 
of CFH/CFHR1 hybrid gene in the pedigree of the patient (Supp. Figure 1) suggests that 
different levels of FH produced the normal CFH allele in these individuals is a plausible 
explanation for the incomplete penetrance of the disease in this pedigree. In addition, 
our patient carries the CFH SNP haplotype associated with increased risk for aHUS, 
inherited from his father (Table 1). 
 
The prognosis for aHUS in patients with complement abnormalities is very poor as a 
result of the progression to renal failure, the TMA in other organs, the ineffectiveness of 
the conventional treatments and the high risk of post-transplant recurrence with loss of 
the graft. TMA occurs systemically in up to 48% of patients and in 38% of cases is 
associated with macro- and microvascular thrombosis. Hence the survival rate of < 40% 
in dialysis patients. The risk of recurrence is higher for carriers of mutations in CFH, 
CFB, C3  and CFH/CFHR1 hybrid gen. The therapeutic response to plasma therapy in 
both native kidney and renal graft is poor and transient. 
 
Identification of the genetic defect in our patient and the high associated risk of 
morbidity/mortality ruled out conventional renal transplant. The discouraging results 
reported with combined liver-kidney transplant led us to also rule out that option, due to 
the complexity of the procedure with particularly high risk of uncontrolled ischemia-
reperfusion-induced complement activation despite extensive plasmatherapy, early graft 
failure and serious infection. 
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The efficacy of eculizumab in blocking complement activity and preserving renal 
function in native-kidney aHUS presented a promising therapeutic option for our 
patient. Treatment was indicated under the terms of compassionate use; it was in fact 
subsequently approved for the treatment of aHUS by the FDA in September 2011 and in 
Europe in November 2011. Our treatment strategy consisted of administering pre-
transplant dose immediately before surgery and 24 hours after  to block the uncontrolled 
complement activation induced by the ischemia/reperfusion. Subsequently, it was given 
weekly for 4 weeks and then at 10-14-day intervals. The patient has remained free of 
clinical manifestations of TMA on this therapy. 
 
A recently-published study reported on 9 patients with aHUS treated pre-transplant with 
eculizumab, 4 of them on combined treatment with plasmapheresis, and 13 cases treated 
for recurrent HUS post-transplant (2). The same strategy as described in our case was 
used in 5 of the 9 patients treated pre-transplant. All the patients who received 
prophylactic treatment remain free of recurrence and the patients treated for relapses 
achieved remission after a median period of 8 months. At over 3 years since transplant, 
this patient has the longest follow-up period to be published so far.  
 
In aHUS patients drug administration intervals longer than two weeks have been 
associated with early relapse and loss of graft refractory to eculizumab and 
plasmapheresis (1). Eculizumab blocks the last phase in the pathogenesis of aHUS: the 
formation of membrane attack complex. Therefore, in high risk mutations the treatment 
is lifelong since the optimal duration of eculizumab treatment has not yet been properly 
addressed (2,13). Close monitoring is vital for early detection of insufficient 
complement inhibition since in some patients the recommended empirical doses may be 
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too low, particularly in the course of respiratory infections, CMV, EBV and 
polyomavirus. This highlights the importance of monitoring for viral replication in these 
patients. The classic markers of extravascular hemolysis do not provide early warning 
of recurrence.  Early markers must therefore be developed which are accessible in 
clinical practice, such as a C5-dependent functional test or the terminal complex test, for 
patient follow-up. Undetectable total hemolytic complement (CH50) activity suggests 
blockage of circulating C5. However, the detection of TMA in a renal biopsy in the 
absence of CH50 in two published cases with post-transplant aHUS suggests that tests 
are not yet sensitive enough for routine monitoring. 
 
In our experience, eculizumab is well tolerated and has kept the patient free of renal and 
systemic TMA over three years of continuous treatment, with no infectious 
complications on prophylaxis with oral penicillin. Graft function remains stable, BP is 
well controlled and he has not developed opportunistic infections. He continues on 
fortnightly eculizumab therapy administered as an outpatient, allowing him to attend 
school and enjoy full social and familial relationships.  
 
This case adds to the evidence on the efficacy of eculizumab prior to kidney 
transplantation in preventing progression of aHUS post-transplant and in the long term 
without the need for plasmapheresis. The development of early markers sensitive to 
disease activity would make it possible in the future to individualize the dose and 
frequency of administration, minimizing the risk of relapse. 
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Tables legends 
Table 1. Complement and Genetic data in patient H142 and relatives 
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Supplementary figure legends 
Supp. Figure 1. Summary of the genetic data in the patient (H142) and their relatives. 
A) The H142 pedigree. The members of the pedigree are identified, and for the affected 
individual H142 and the other carriers of the CFH/CFHR1 hybrid gene, the levels of 
total plasma FH and of the normal FH (402Y) are indicated. Notice that H142 also 
inherits an aHUS risk allele from his father. 
B) Summary of the MLPA data. Graphs illustrate the number of copies of different 
exons in the CFH-CFHR1 region. Notice that levels of CFH exon 23, but not CFHR1 
exon 6, are decreased in the patient and three of their relatives indicating they are 
carriers of a CFH/CFHR1 hybrid gene.  
C) Diagram of the FH molecule resulting from the CFH/CHFR1 hybrid gene. The 
circles indicate each of the 20 SCR domain units that compose FH. The locations of the 
four amino acid differences found are indicated. Notice that the two changes in SCRs 15 
and 16 are rare polymorphisms with no functional relevance (Tortajada et al. Kidney 
International, 2012).  
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Table 1. 
Complement data ID 
C3 levels 
(80-177mg/dL) 
C4 levels 
(14-47mg/dL)
fI levels 
(% of control) 
fB antigenic 
(7-28 mg/dL) 
fB hemolytic 
(% of control) 
fH levels^ 
(12-56mg/dL) 
fH hemolytic 
(% of lysis) Anti-fH 
H142 Index case (*) 94 24 >100 11 100 20 [9.6] 100 No 
H142P Healthy 117 30 >100 13 100 32 Neg. No
H142M Healthy (*) 100 32 >100 15 100 32 [17] 40 No
H142P1 Healthy 86 21 >100 8 100 39 Neg. No
H142P2 Healthy 109 23 >100 11 100 33 Neg. No
H142P3 Healthy (*) 133 32 >100 11 100 35 [17.5] 64 No
H142P4 Healthy (*) 116 14 - 9 100 52 [27] 38 No 
H142P5 Healthy 119 23 - 18 100 - Neg. No 
Genetic data CFH CFHRs MCP Mutations other genes 
 ID Muta- tions 
Hybrid 
gene 
Risk
haplotype 
S890I and V1007L
polymorphisms Del(R3-R1) 
Muta- 
tions 
Risk
haplotype CFI CFB C3 THBD 
H142 Index case No Yes Yes (Het) Yes 
No No No No No No No 
H142P Healthy - No Yes (Hom) No No - No - - - - 
H142M Healthy - Yes No Yes No - Yes (Het) - - - - 
H142P1 Healthy - No Yes (Het) No No - Yes (Het) - - - - 
H142P2 Healthy - No Yes (Het) No No - No - - - - 
H142P3 Healthy - Yes No Yes No - Yes (Het) - - - - 
H142P4 Healthy - Yes - Yes No - No - - - - 
H142P5 Healthy - No No No No - Yes (Hom) - - - - 
CFH risk haplotype: rs3753394 (c.-331T); rs800292 (c.184G); rs1061170 (c.1204T); rs3753396 (c.2016G); rs1065489 (c.2808T) ;MCP risk haplotype: rs2796267 
(c.-652G); rs2796268  (c.-366AG); rs1962149 (c.989-78A); rs7144 (*897C).  (*) These individuals carry the CFH::CFHR1 hybrid gene (Venables et al. PLoS Med 
2006)(^)  Levels of normal factor H are shown between brackets(-), Not done 

